ATE459618T1 - 3-piperidinylisochroman-5-ole als dopaminagonisten - Google Patents

3-piperidinylisochroman-5-ole als dopaminagonisten

Info

Publication number
ATE459618T1
ATE459618T1 AT05740005T AT05740005T ATE459618T1 AT E459618 T1 ATE459618 T1 AT E459618T1 AT 05740005 T AT05740005 T AT 05740005T AT 05740005 T AT05740005 T AT 05740005T AT E459618 T1 ATE459618 T1 AT E459618T1
Authority
AT
Austria
Prior art keywords
piperidinylisochromane
ols
dopamine agonists
dopamine
agonists
Prior art date
Application number
AT05740005T
Other languages
English (en)
Inventor
Gregory Shutske
Keith Harris
Kenneth Bordeau
Michael Angelastro
Stanly John
Joseph Klein
Jinqi Lu
Catherine Bomont
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE459618T1 publication Critical patent/ATE459618T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT05740005T 2004-04-29 2005-04-27 3-piperidinylisochroman-5-ole als dopaminagonisten ATE459618T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56655704P 2004-04-29 2004-04-29
PCT/US2005/014487 WO2005111025A1 (en) 2004-04-29 2005-04-27 3-piperidinylisochroman-5-ols as dopamine agonists

Publications (1)

Publication Number Publication Date
ATE459618T1 true ATE459618T1 (de) 2010-03-15

Family

ID=34967397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05740005T ATE459618T1 (de) 2004-04-29 2005-04-27 3-piperidinylisochroman-5-ole als dopaminagonisten

Country Status (11)

Country Link
US (1) US7919508B2 (de)
EP (1) EP1749001B1 (de)
JP (1) JP4685861B2 (de)
AR (1) AR050245A1 (de)
AT (1) ATE459618T1 (de)
DE (1) DE602005019719D1 (de)
DK (1) DK1749001T3 (de)
ES (1) ES2342083T3 (de)
PT (1) PT1749001E (de)
TW (1) TW200607802A (de)
WO (1) WO2005111025A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3587400T1 (sl) * 2013-10-22 2024-05-31 Chiesi Farmaceutici S.P.A. Postopek za pripravo zaviralca pde4
JP6564394B2 (ja) * 2014-04-28 2019-08-21 ファイザー・インク 複素環式化合物およびそのドーパミンd1リガンドとしての使用
ES2821821T3 (es) * 2014-10-08 2021-04-27 UCB Biopharma SRL Derivados de tetrahidroisoquinolina
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
KR20190065246A (ko) * 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN111196781B (zh) * 2018-11-16 2023-07-28 湖南中南制药有限责任公司 一种改进的制备五氟利多的方法
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
JP4177461B2 (ja) * 1997-02-07 2008-11-05 アベンティス・ファーマスーティカルズ・インコーポレイテッド 抗精神病剤として有用な(4−ピペリジニル)−1h−2−ベンゾピラン誘導体
US6004982A (en) * 1997-09-15 1999-12-21 Hoechst Marion Roussel, Inc. 4-piperidinyl) H-2-benzopyran derivatives useful as antipsychotic agents

Also Published As

Publication number Publication date
EP1749001B1 (de) 2010-03-03
DK1749001T3 (da) 2010-06-28
WO2005111025A1 (en) 2005-11-24
PT1749001E (pt) 2010-05-31
US20070099955A1 (en) 2007-05-03
AR050245A1 (es) 2006-10-11
JP4685861B2 (ja) 2011-05-18
JP2007535548A (ja) 2007-12-06
US7919508B2 (en) 2011-04-05
ES2342083T3 (es) 2010-07-01
TW200607802A (en) 2006-03-01
EP1749001A1 (de) 2007-02-07
DE602005019719D1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
DE602006007563D1 (de) Agonisten
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DE602005017215D1 (de) Thiadiazolidinone als GSK3-Inhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DK1928882T3 (da) (s)-n-methylnaltrexon
ATE443753T1 (de) Nuancierungsmittel
DE602006016566D1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
NO20055686D0 (no) Sammensetning
DE602005008986D1 (de) Substituierte hydantoine
DE602005015204D1 (de) Oxadiazolonderivate als ppar-delta-agonisten
ATE459618T1 (de) 3-piperidinylisochroman-5-ole als dopaminagonisten
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DK1904404T3 (da) Mærkede uorganiske additiver
DE602006021285D1 (de) Mikrotomklinge
FI20050681A0 (fi) Paikoitusmenetelmä
DE502006002822D1 (de) Ges
DE502004004640D1 (de) Verschwenkvorrichtung
FI20050336A0 (fi) Pidike
FI6365U1 (fi) Näytteenotin
ITPZ20060004U1 (it) Bitelefono mobile (bicellulare)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1749001

Country of ref document: EP